Stellar Pharmaceutic, Inc. (SLXCF.OB) Reports Profitability for 2009
Stellar Pharmaceuticals Inc. is a Canadian pharmaceutical developer and marketer of three products based on its core polysaccharide technology. The three products are: NeoVisc – for the symptomatic treatment of osteoarthritis, Uracyst – for the treatment of interstitial cystitis, an inflammatory disease of the urinary bladder wall and NMP22 BladderChek – a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. The company today announced financial results for the year ended December 31, 2009. All results are reported in Canadian dollars. Stellar's total revenues for 2009 were $3,581.300, up 39.9 percent from 2008 results. The increase in revenues…